APA (7th ed.) Citation

Ishibashi, R., Inaba, Y., Koshizaka, M., Takatsuna, Y., Tatsumi, T., Shiko, Y., . . . Yokote, K. (2024). Sodium‐glucose co‐transporter 2 inhibitor therapy reduces the administration frequency of anti‐vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti‐vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database. Diabetes, Obesity & Metabolism, 26(4), 1510. https://doi.org/10.1111/dom.15454

Chicago Style (17th ed.) Citation

Ishibashi, Ryoichi, et al. "Sodium‐glucose Co‐transporter 2 Inhibitor Therapy Reduces the Administration Frequency of Anti‐vascular Endothelial Growth Factor Agents in Patients with Diabetic Macular Oedema with a History of Anti‐vascular Endothelial Growth Factor Agent Use: A Cohort Study Using the Japanese Health Insurance Claims Database." Diabetes, Obesity & Metabolism 26, no. 4 (2024): 1510. https://doi.org/10.1111/dom.15454.

MLA (9th ed.) Citation

Ishibashi, Ryoichi, et al. "Sodium‐glucose Co‐transporter 2 Inhibitor Therapy Reduces the Administration Frequency of Anti‐vascular Endothelial Growth Factor Agents in Patients with Diabetic Macular Oedema with a History of Anti‐vascular Endothelial Growth Factor Agent Use: A Cohort Study Using the Japanese Health Insurance Claims Database." Diabetes, Obesity & Metabolism, vol. 26, no. 4, 2024, p. 1510, https://doi.org/10.1111/dom.15454.